* Acutus Medical Inc AFIB.OQ AFIB.O is expected to show a
rise in quarterly revenue when it reports results on November
11.
* The Carlsbad, California-based company is expected to report
a 79.2% increase in revenue to $5.685 million from $3.17 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Acutus Medical Inc is
for a loss of 87 cents per share. For the same quarter last
year, the company reported a loss of $1.95 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Acutus Medical
Inc is $18.5, about 57.7% above its last closing price
of $7.83.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2021 -0.92 -0.84 -1.02 Missed -21.7
Mar. 31 2021 -0.85 -0.81 -1.04 Missed -28.1
Dec. 31 2020 -0.74 -0.72 -1.05 Missed -45.4
Sep. 30 2020 -1.06 -0.99 -1.95 Missed -96.6
Jun. -1.03 -1.03 -32.24 Missed -3,030
30 2020 .1
This summary was machine generated November 9 at 22:12 GMT. All
figures in US dollars unless otherwise stated